Rachael Sexton

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 868 citations · Full text

Hematological Malignancy, Dexamethasone Versus Lenalidomide, Oncology +9

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Brian G.M. Durie, Antje Hoering, Rachael Sexton et al. · Blood Cancer Journal · 2020 · 246 citations · Full text

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed et al. · Blood · 2013 · 196 citations

Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701)

Carolina Porras, Jesse Nodora, Rachael Sexton et al. · Cancer Causes & Control · 2012 · 141 citations · Full text

Swog Trial S0701, Clinical Epidemiology, Gastrointestinal Virus +5

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Saad Z. Usmani, Antje Hoering, Sikander Ailawadhi et al. · The Lancet Haematology · 2020 · 122 citations · Full text

Hematological Malignancy, Oncology, Hematology +6